Evidence map›Paper›PMID 42807944›Full record

ArticleInternational journal of biological sciences2026

Spatial, single-nucleus and pathological profiling of the invasive front in early hepatocellular carcinoma for characterizing specific leading-edge cell niche and improving recurrence modeling.

Xicheng Wang, Xiaolan Mu, Yong Fu, Wei Dong, Wenfeng Lu, Xiuhua Li, Yanxiang Song, Changcheng Liu, Baoju Hou, Haibin Zhang and 3 more

Abstract read
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xicheng WangInstitute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200123, China.
Xiaolan MuInstitute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200123, China.
Yong FuDepartment of Liver Surgery V, The Eastern Hepatobiliary Surgery Hospital, Third Affiliated Hospital of Naval Medical University, Shanghai 200438, P. R. China.
Wei DongDepartment of pathology, The Eastern Hepatobiliary Surgery Hospital, Third Affiliated Hospital of Naval Medical University, Shanghai 200438, P. R. China.
Wenfeng LuDepartment of Liver Surgery V, The Eastern Hepatobiliary Surgery Hospital, Third Affiliated Hospital of Naval Medical University, Shanghai 200438, P. R. China.
Xiuhua LiInstitute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200123, China.
Yanxiang SongInstitute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200123, China.
Changcheng LiuInstitute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200123, China.
Baoju HouInstitute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200123, China.
Haibin ZhangDepartment of Liver Surgery V, The Eastern Hepatobiliary Surgery Hospital, Third Affiliated Hospital of Naval Medical University, Shanghai 200438, P. R. China.
Xiong ChenDepartment of Oncology, Mengchao Hepatobiliary Hospital of Fujian Medical University, 350028, Fuzhou, Fujian, China.
Yongchao CaiInstitute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200123, China.
Zhiying HeInstitute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200123, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor leading edge (TLE) is a critical region where tumor cells interact with the microenvironment to drive invasion and metastasis; however, its cellular architecture in early hepatocellular carcinoma (HCC) remains poorly understood. Here, we integrated single-nucleus RNA-seq (snRNA-seq), spatial transcriptomics, and computational pathology to investigate TLE in early HCC. We annotated 35 cell subpopulations and identified STMN1-high tumor cells as a key malignant subset enriched at the invasive front, interacting with Treg, plasma B, LAMP3⁺ dendritic cells and SPP1⁺ macrophages. Spatial analysis revealed three co-localized cell pairs-(SPP1⁺ macrophages co-localized with Tip-like and inflammatory endothelial cells), (LAMP3⁺ DCs co-localized with naive T cells), and (plasma B cells co-localized with cancer-associated fibroblasts)-forming a leading-edge tumor microenvironment (L-TME) niche associated with early relapse. We developed an L-TME-related machine-learning benchmark framework incorporating 71 imaging features (65 deep-learning + 6 pathological) based on the snRNA-seq, spatial transcriptomics and pathomics. The pathology model achieved robust performance (mean C-index=0.77) and successfully predicted the recurrence of early HCC (log-rank

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHumansNeoplasm Recurrence, LocalSpatial TranscriptomicsTumor Microenvironmentearly HCCpathologyrecurrenceSTMN1-high tumor cellstumor leading-edge area (TLE)

Identifiers

PMID42807944
PMCPMC13618224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.